Exelixis, Inc.  

(Public, NASDAQ:EXEL)   Watch this stock  
Find more results for EXEL
23.78
-0.29 (-1.20%)
Jun 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 23.78 - 24.54
52 week 7.20 - 24.85
Open 24.11
Vol / Avg. 31.69M/4.69M
Mkt cap 6.87B
P/E 2,220.35
Div/yield     -
EPS 0.01
Shares 292.51M
Beta 1.98
Inst. own 82%
Aug 1, 2017
Q2 2017 Exelixis Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 13, 2017
Exelixis Inc at William Blair Growth Stock Conference
May 24, 2017
Exelixis Inc Annual Shareholders Meeting
May 3, 2017
Exelixis Inc at Deutsche Bank Health Care Conference - Webcast
May 1, 2017
Q1 2017 Exelixis Inc Earnings Call - Webcast
May 1, 2017
Q1 2017 Exelixis Inc Earnings Release
Apr 4, 2017
Exelixis Inc at Needham Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 20.65% -36.68%
Operating margin 24.96% -21.95%
EBITD margin - -13.69%
Return on average assets 11.33% -15.13%
Return on average equity 64.08% -
Employees 287 -
CDP Score - -

Address

210 E Grand Ave
SOUTH SAN FRANCISCO, CA 94080-4811
United States - Map
+1-650-8377000 (Phone)
+1-650-8378300 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board, Co-Founder
Age: 68
Bio & Compensation  - Reuters
Michael M. Morrissey Ph.D. President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Christopher J. Senner Chief Financial Officer, Executive Vice President
Age: 49
Bio & Compensation  - Reuters
Gisela M. Schwab M.D. President - Product Development and Medical Affairs, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Peter Lamb Ph.D. Executive Vice President - Scientific Strategy, Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Jeffrey J. Hessekiel J.D. Executive Vice President, General Counsel, Secretary
Age: 48
Bio & Compensation  - Reuters
Patrick Haley Senior Vice President - Commercial
Age: 41
Bio & Compensation  - Reuters
Charles M. Cohen Ph.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Carl B. Feldbaum Esq. Independent Director
Age: 73
Bio & Compensation  - Reuters
Alan M. Garber M.D. Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters